HLX 25
Alternative Names: HLX-25Latest Information Update: 19 Jun 2021
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Non-small cell lung cancer